Figure 3.

Administration of anti–IL-17 treatment inhibits relapse. A: Clinical scores for animals treated from PSD 28. IL-17A–treated animals were less disabled and relapsed later than those that received control IgG. ^∗P < 0.05 EAE+anti–IL-17A versus EAE+IgG control mice. B: Record of the weights of the animals revealed no significant differences between animals with EAE. Data are shown as means ± SEM. n = 25 in the EAE+anti–IL-17A group; n = 24 in the EAE+IgG group; n = 12 in the CFA control and naive group. Arrows indicate the day of administration of vehicle or anti–1L-17A.